Q2 EPS Forecast for Avadel Pharmaceuticals Lifted by Analyst

Avadel Pharmaceuticals plc (NASDAQ:AVDL - Free Report) - Investment analysts at Lifesci Capital lifted their Q2 2025 earnings per share (EPS) estimates for shares of Avadel Pharmaceuticals in a note issued to investors on Thursday, June 5th. Lifesci Capital analyst M. Belghiti now expects that the company will post earnings of $0.05 per share for the quarter, up from their previous forecast of $0.02. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Avadel Pharmaceuticals' Q4 2025 earnings at $0.19 EPS.

A number of other analysts have also recently weighed in on AVDL. HC Wainwright reissued a "buy" rating and set a $21.00 price objective on shares of Avadel Pharmaceuticals in a report on Tuesday, March 4th. Needham & Company LLC restated a "buy" rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $19.43.

Avadel Pharmaceuticals Price Performance

Shares of NASDAQ AVDL traded down $0.55 during midday trading on Monday, hitting $9.34. 1,524,175 shares of the company's stock were exchanged, compared to its average volume of 1,258,533. The firm's fifty day simple moving average is $8.69 and its 200-day simple moving average is $8.88. The company has a market cap of $903.54 million, a PE ratio of -11.82 and a beta of 1.45. Avadel Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $17.30.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. Avadel Pharmaceuticals had a negative net margin of 52.53% and a negative return on equity of 93.34%. The firm had revenue of $52.51 million during the quarter, compared to the consensus estimate of $50.57 million. During the same quarter in the previous year, the firm posted ($0.30) earnings per share. The company's revenue was up 93.2% compared to the same quarter last year.

Hedge Funds Weigh In On Avadel Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its holdings in shares of Avadel Pharmaceuticals by 2.0% in the fourth quarter. Rhumbline Advisers now owns 124,137 shares of the company's stock valued at $1,305,000 after purchasing an additional 2,492 shares during the period. Nations Financial Group Inc. IA ADV acquired a new position in Avadel Pharmaceuticals in the 4th quarter valued at $163,000. AlphaCentric Advisors LLC purchased a new position in Avadel Pharmaceuticals during the 4th quarter worth $354,000. Sanctuary Advisors LLC acquired a new stake in shares of Avadel Pharmaceuticals in the 4th quarter worth $140,000. Finally, Investors Asset Management of Georgia Inc. GA ADV boosted its holdings in shares of Avadel Pharmaceuticals by 21.4% in the fourth quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 120,275 shares of the company's stock valued at $1,264,000 after acquiring an additional 21,200 shares in the last quarter. Institutional investors and hedge funds own 69.19% of the company's stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.